 Christine McMahon
Concepts (82)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 21 | 2025 | 630 | 3.900 |
Why?
| | fms-Like Tyrosine Kinase 3 | 3 | 2019 | 48 | 1.370 |
Why?
| | Aniline Compounds | 3 | 2019 | 102 | 1.340 |
Why?
| | Pyrazines | 3 | 2019 | 90 | 1.320 |
Why?
| | Myelodysplastic Syndromes | 2 | 2025 | 135 | 1.010 |
Why?
| | Hematopoietic Stem Cell Transplantation | 5 | 2025 | 622 | 0.870 |
Why?
| | Transplantation Conditioning | 2 | 2024 | 170 | 0.740 |
Why?
| | Azacitidine | 5 | 2023 | 140 | 0.730 |
Why?
| | Antineoplastic Agents | 3 | 2025 | 2129 | 0.660 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 8 | 2025 | 227 | 0.660 |
Why?
| | Protein Kinase Inhibitors | 3 | 2019 | 916 | 0.600 |
Why?
| | Clonal Evolution | 1 | 2019 | 45 | 0.600 |
Why?
| | ras Proteins | 1 | 2019 | 153 | 0.580 |
Why?
| | Sulfonamides | 7 | 2025 | 513 | 0.530 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2019 | 801 | 0.530 |
Why?
| | Molecular Targeted Therapy | 2 | 2024 | 411 | 0.520 |
Why?
| | Mutation | 8 | 2025 | 3958 | 0.460 |
Why?
| | Immunotherapy | 1 | 2018 | 641 | 0.420 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 9 | 2024 | 1692 | 0.370 |
Why?
| | Proto-Oncogene Proteins | 2 | 2025 | 648 | 0.360 |
Why?
| | Recurrence | 4 | 2025 | 1060 | 0.330 |
Why?
| | Prognosis | 5 | 2025 | 4030 | 0.310 |
Why?
| | Signal Transduction | 1 | 2019 | 5079 | 0.240 |
Why?
| | Activin Receptors, Type II | 1 | 2025 | 12 | 0.240 |
Why?
| | Immunoglobulin Fc Fragments | 1 | 2025 | 41 | 0.230 |
Why?
| | Drug Approval | 1 | 2025 | 88 | 0.230 |
Why?
| | Transplantation, Haploidentical | 1 | 2024 | 22 | 0.220 |
Why?
| | Oligonucleotides | 1 | 2025 | 148 | 0.220 |
Why?
| | Myeloid-Lymphoid Leukemia Protein | 1 | 2024 | 70 | 0.210 |
Why?
| | Leukocytosis | 2 | 2020 | 30 | 0.210 |
Why?
| | Cord Blood Stem Cell Transplantation | 1 | 2024 | 99 | 0.210 |
Why?
| | Histone-Lysine N-Methyltransferase | 1 | 2024 | 136 | 0.190 |
Why?
| | Recombinant Fusion Proteins | 1 | 2025 | 665 | 0.190 |
Why?
| | Humans | 23 | 2025 | 137585 | 0.190 |
Why?
| | Nuclear Proteins | 1 | 2025 | 712 | 0.170 |
Why?
| | Aged, 80 and over | 5 | 2025 | 7635 | 0.160 |
Why?
| | Survival | 1 | 2019 | 38 | 0.160 |
Why?
| | Decision Support Systems, Clinical | 1 | 2022 | 226 | 0.150 |
Why?
| | Disease Management | 2 | 2024 | 628 | 0.150 |
Why?
| | Retreatment | 1 | 2018 | 72 | 0.150 |
Why?
| | Risk Factors | 2 | 2025 | 10388 | 0.140 |
Why?
| | Aged | 8 | 2025 | 23961 | 0.130 |
Why?
| | Treatment Outcome | 5 | 2025 | 10811 | 0.130 |
Why?
| | Middle Aged | 9 | 2025 | 33479 | 0.130 |
Why?
| | Single-Cell Analysis | 1 | 2019 | 313 | 0.130 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2019 | 539 | 0.120 |
Why?
| | Adult | 9 | 2025 | 37929 | 0.120 |
Why?
| | Spiro Compounds | 2 | 2025 | 14 | 0.120 |
Why?
| | Young Adult | 5 | 2024 | 13209 | 0.110 |
Why?
| | Benzamides | 2 | 2025 | 216 | 0.110 |
Why?
| | Induction Chemotherapy | 2 | 2024 | 76 | 0.100 |
Why?
| | Cell Differentiation | 1 | 2019 | 1991 | 0.090 |
Why?
| | Biomarkers, Tumor | 1 | 2018 | 1276 | 0.090 |
Why?
| | Leukocyte Count | 2 | 2024 | 329 | 0.090 |
Why?
| | Male | 9 | 2025 | 67762 | 0.090 |
Why?
| | Female | 9 | 2025 | 73304 | 0.080 |
Why?
| | Leukapheresis | 2 | 2020 | 21 | 0.080 |
Why?
| | Retrospective Studies | 5 | 2024 | 15657 | 0.070 |
Why?
| | Splicing Factor U2AF | 1 | 2023 | 16 | 0.050 |
Why?
| | Antigens, CD34 | 1 | 2023 | 88 | 0.050 |
Why?
| | Gene Rearrangement | 1 | 2024 | 150 | 0.050 |
Why?
| | Chemotaxis | 1 | 2023 | 131 | 0.050 |
Why?
| | Neoplasm, Residual | 1 | 2023 | 133 | 0.050 |
Why?
| | Graft vs Host Disease | 1 | 2024 | 252 | 0.050 |
Why?
| | Stem Cell Transplantation | 1 | 2023 | 176 | 0.050 |
Why?
| | RNA Splicing | 1 | 2023 | 269 | 0.050 |
Why?
| | Allografts | 1 | 2021 | 146 | 0.040 |
Why?
| | Remission Induction | 1 | 2020 | 288 | 0.040 |
Why?
| | Neoplastic Stem Cells | 1 | 2023 | 399 | 0.040 |
Why?
| | Mice, Transgenic | 1 | 2023 | 2167 | 0.040 |
Why?
| | Neutrophils | 1 | 2023 | 1238 | 0.030 |
Why?
| | Machine Learning | 1 | 2022 | 493 | 0.030 |
Why?
| | Odds Ratio | 1 | 2020 | 1070 | 0.030 |
Why?
| | Phenotype | 1 | 2025 | 3196 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2020 | 1509 | 0.030 |
Why?
| | Disease Progression | 1 | 2023 | 2757 | 0.030 |
Why?
| | Risk Assessment | 1 | 2024 | 3457 | 0.030 |
Why?
| | Adolescent | 2 | 2024 | 21513 | 0.030 |
Why?
| | Logistic Models | 1 | 2020 | 2074 | 0.030 |
Why?
| | Mice | 1 | 2023 | 17787 | 0.020 |
Why?
| | Child | 1 | 2024 | 21935 | 0.010 |
Why?
| | Animals | 1 | 2023 | 36940 | 0.010 |
Why?
|
|
McMahon's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|